Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.51 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503011 | 0.99 | MAPT (0.52) | MAPTSMN1; SMN2RAB9AGAAMEN1 | |
| SCHEMBL27584176 | 0.89 | MAPT (0.50) | MAPTSMN1; SMN2RAB9AGAAMEN1 | |
| SCHEMBL27601764 | 0.87 | MAPT (0.55) | MAPTSMN1; SMN2RAB9AGAAMEN1 | |
| SCHEMBL5499030 | 0.84 | MAPT (0.49) | MAPTSMN1; SMN2RAB9AGAAMEN1 | |
| SCHEMBL5492140 | 0.82 | MAPT (0.47) | MAPTSMN1; SMN2RAB9AGAAMEN1 | |
| SCHEMBL5487242 | 0.80 | PYGL (0.54) | MAPTSMN1; SMN2RAB9AGAAMEN1 | |
| SCHEMBL27509164 | 0.80 | THRB (0.54) | MAPTSMN1; SMN2RAB9AGAAMEN1 | |
| SCHEMBL5491138 | 0.79 | PYGL (0.52) | MAPTSMN1; SMN2RAB9AGAAMEN1 | |
| SCHEMBL5493301 | 0.78 | RAB9A (0.55) | MAPTSMN1; SMN2RAB9AGAAMEN1 | |
| SCHEMBL5491231 | 0.78 | ACLY (0.51) | MAPTSMN1; SMN2RAB9AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297696-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1363897-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | LABORDE EDGARDO (US) | 2005-03-10 | — | — | US | disclosed |
| US-6809113-B2 | FOR THERAPY OF ARTHRITIS, ASTHMA, ATHEROSCLEROSIS, DIABETIC NEPHROPATHY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, MULTIPLE SCLEROSIS, NEPHRITIS, PANCREATITIS, PULMONARY FIBROSIS, PSORIASIS, RESTENOSIS TRANSPLANT REJECTION | TELIK, INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1363897-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070509-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | MAPT 1663/4885SMN1; SMN2 3141/4885RAB9A 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.